Immunocryosurgery for basal cell carcinoma: impact on circulating CD4⁺ CD25^high T regulatory cells and serum cytokines

Eur J Dermatol. 2020 Oct 1;30(5):605-606. doi: 10.1684/ejd.2020.3864.

Authors

Georgios Gaitanis¹, Areti Ganiatsa¹, Georgios Vartholomatos², Achilleas Karamoutsios², Periklis Pappas³, Ioannis D Bassukas¹

Affiliations

¹ Department of Skin and Venereal Diseases, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
² Molecular Biology Unit, Laboratory of Haematology, University Hospital of Ioannina, Ioannina, Greece.
³ Department of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.

PMID: 32959782
DOI: 10.1684/ejd.2020.3864

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Antineoplastic Agents / therapeutic use*
Carcinoma, Basal Cell / blood
Carcinoma, Basal Cell / therapy*
Combined Modality Therapy
Cryosurgery
Humans
Imiquimod / therapeutic use*
Interferon-alpha / blood
Interleukin-10 / blood
Lymphocyte Count
Male
Middle Aged
Skin Neoplasms / blood
Skin Neoplasms / therapy*
T-Lymphocytes, Regulatory*
Tumor Necrosis Factor-alpha / blood

Substances

Antineoplastic Agents
IL10 protein, human
Interferon-alpha
Tumor Necrosis Factor-alpha
Interleukin-10
Imiquimod